methyl (E)-2-propyl-2-pentenoate | 78435-49-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl (E)-2-propyl-2-pentenoate
• 英文别名: (E/Z)-2-Propyl-2-pentenoic Acid Methyl Ester；methyl (E)-2-propylpent-2-enoate
• CAS: 78435-49-1
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: HSEARQSRPMUTTB-SOFGYWHQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl (E)-2-propyl-2-pentenoate 生成 (E)-2-丙基戊-2-烯酸
  参考文献：
  名称：

  Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds

  摘要：

  A family of compounds based upon the chemical structure of valproate were synthesized and assayed for their ability to inhibit glycogen synthase kinase (GSK)-3 alpha and beta activity in vitro. This data is correlated to the known anti-convulsant properties of these compounds in order to determine the potential role of GSK-3 inhibition in the therapeutic efficacy of these drugs. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.013
• 作为产物：
  描述：

  3-Hydroxy-2-propyl-pentanoic acid methyl ester 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 methyl (E)-2-propyl-2-pentenoate
  参考文献：
  名称：

  Structure-Activity Relationships of Unsaturated Analogs of Valproic Acid

  摘要：

  The principal metabolite of valproic acid (VPA), 2-ene VPA, appears to share most of VPA's pharmacological and therapeutic properties while lacking its hepatotoxicity and teratogenicity, thus making it a useful lead compound for the development of safer antiepileptic drugs. Analogues of 2-ene VPA were evaluated for anticonvulsant activity in mice using the subcutaneous pentylenetetrazole test. Cyclooctylideneacetic acid exhibited a potency markedly exceeding that of VPA itself with only modest levels of sedation. Potency, as either ED(50) or brain concentration, was highly correlated (r > 0.85) with volume and lipophilicity rather than with one of the shape parameters calculated by molecular modeling techniques, arguing against the existence of a specific receptor site. Instead, a role for the plasma membrane in mediating the anticonvulsant effect is suggested.

  DOI：

  10.1021/jm00017a024

文献信息

• IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140206675A1

  公开（公告）日：2014-07-24

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, L 2 -, and L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (Aβ) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination nation with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers disease, are also disclosed.

  在其不同实施例中，本发明提供某些亚氨基噻二嗪二氧化物化合物，包括化合物公式（I）：（I），并包括其立体异构体和药学上可接受的盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、L2-和L3-各自独立选择并按照定义选定。本发明的新型亚氨基噻二嗪二氧化物化合物出人意料地发现具有预期的性质，这些性质使它们有望成为BACE抑制剂和/或用于治疗和预防与β-淀粉样蛋白（Aβ）产生相关的各种病理的优势。本发明还揭示了包括一个或多个此类化合物（独立和与一个或多个其他活性剂联合使用）的药物组合物，并揭示了用于制备和治疗与淀粉样β（Aβ）蛋白相关的病理，包括阿尔茨海默病的方法。
• ABAD A.; ARNO M.; PEDRO J. R.; SEOANE E., CHEM. AND IND., 1981, NO 5, 157-158
  作者：ABAD A.、 ARNO M.、 PEDRO J. R.、 SEOANE E.

  DOI：——

  日期：——
• US7176240B2
  申请人：——

  公开号：US7176240B2

  公开（公告）日：2007-02-13
• US7569608B2
  申请人：——

  公开号：US7569608B2

  公开（公告）日：2009-08-04
• US7569609B2
  申请人：——

  公开号：US7569609B2

  公开（公告）日：2009-08-04